Citations

Clear

6273 citation(s) found for "To, Andrew".

Vascular burden and Alzheimer disease pathologic progression
Lo, Raymond Y. , Jagust, William J. , Weiner, Michael W. , Aisen, Paul , Petersen, Ronald , Trojanowki, John Q., Liu, Enchi , Montine, Tom, Petersen, Ronald, Gamst, Anthony, Thomas, Ronald G. , Walter, Sarah , Gessert, Devon, Sather, Tamie, Kornak, John , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene, DeCarli, Charles , Bandy, Dan, Foster, Norm, Reiman, Eric M. , Mathis, Chet, Cairns, Nigel J., Taylor‐Reinwald, Lisa, Shaw, Les, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Foroud, Tatiana M., Potkin, Steven, Kachaturian, Zaven, Frank, Richard , Molchan, Susan, Quinn, Joseph, Lind, Betty, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James, Vanderswag, Helen, Heidebrink, Judith L. , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Bell, Karen L. , Carroll, Maria , Leon, Sue, Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Clark, David, Grossman, Hillel, Mitsis, Effie, Romirowsky, Aliza, deToledo‐Morrell, Leyla, Duara, Ranjan , Varón, Daniel , Roberts, Peggy, Albert, Marilyn, Onyike, Chiadi, Kielb, Stephanie , Glodzik, Lidia , Santi, Susan De , Doraiswamy, P. Murali , Petrella, Jeffrey R. , Coleman, R. Edward, Arnold, Steven E. , Karlawish, Jason H., Smith, Charles D., Jicha, Gregory A. , Hardy, Peter , Oakley, MaryAnn, Simpson, Donna M., Goldstein, Bonnie S., Martin, Kim, Makino, Kelly M., Ismail, M. Saleem , Brand, Connie, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Mathews, Dana, Quiceno, Mary , King, Richard, Weiner, Myron, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Swerdlow, Russell H. , Apostolova, Liana , Lu, Po H. , Bartzokis, George, Graff‐Radford, Neill R. , Parfitt, Francine, Farlow, Martin R. , Hake, Ann Marie , Matthews, Brandy R., Herring, Scott, Dyck, Christopher H. van , Carson, Richard E. , MacAvoy, Martha G., Chertkow, Howard , Bergman, Howard , Hosein, Chris, Black, Sandra, Stefanovic, Dr Bojana, Caldwell, Curtis, Hsiung, Ging‐Yuek Robin , Mudge, Benita, Assaly, Michele, Kertesz, Andrew, Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Mesulam, Marek-Marsel, Lipowski, Kristina, Wu, Chuang‐Kuo, Johnson, Nancy , Sadowsky, Carl, Villena, Teresa, Johnson, Kathleen, Reynolds, Brigid, Johnson, Keith A., Marshall, Gad A. , Frey, Meghan , Yesavage, Jerome A. , Taylor, Joy L. , Lane, Barton , Rosen, Allyson , Tinklenberg, Jared, Sabbagh, Marwan N. , Belden, Christine M. , Jacobson, Sandra A. , Kowall, Neil W. , Budson, Andrew E. , Johnson, Patricia Lynn, Wolday, Saba, Bwayo, Salome K., Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Fletcher, Evan, Olichney, John , Kittur, Smita, Borrie, Michael, Lee, T‐Y, Bartha, Dr Rob, Asthana, Sanjay , Carlsson, Cynthia M., Preda, Adrian , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Blank, Karen, Anderson, Karen, Santulli, Robert B. , Schwartz, Eben S., Williamson, Jeff D. , Garg, Pradeep , Watkins, Franklin, Ott, Brian R. , Querfurth, Henry, Tremont, Geoffrey , Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J. , Mintzer, Jacobo , Longmire, Crystal Flynn, Spicer, Kenneth, Rachinsky, Irina, Rogers, John , Drost, Dick, Lee, Ting‐Yim , Jack, Clifford R. , Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Saykin, Andrew J. , Morris, John C. , Donohue, Michael , Harvey, Danielle , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Koeppe, Robert A. , Chen, Kewei , Mathis, Chet, Lee, Virginia M.‐Y. , Shen, Li , Snyder, Peter J. , Kaye, Jeffrey , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Ances, Beau M. , Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , Karlawish, Jason , Wolk, David A. , López, Oscar L. , Porsteinsson, Anton P. , Womack, Kyle , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Stefanovic, Bojana , Feldman, Howard , Kerwin, Diana , Martínez, Walter Fabián , Turner, Raymond Scott , Sperling, Reisa Anne , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Carmichael, Owen , Johnson, Sterling C. , Nguyen, Dana R. , Reeder, Stephanie, Scharre, Douglas W. , Pearlson, Godfrey D. , Sink, Kaycee M. , Miller, Bruce L. , Finger, Elizabeth C. , Preda, Adrian , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | September 13, 2012 | Volume: 79 | Issue: 13 | Pages: 1349-1355

10.1212/wnl.0b013e31826c1b9d | PMID 22972646 Get It

The International Assembly of Pediatric Anesthesiologists
Flick, Randall P., Davidson, Andrew J

Mayo Clinic

Pediatric Anesthesia | September 12, 2012 | Volume: 22 | Issue: 10 | Pages: 943-943

10.1111/pan.12011 | PMID 22967149 Get It

Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping
Dong, Maoqing , Ball, Alicja M., Makhoul, Joshua, Lam, Polo C.‐H., Pinon, Delia I., Orry, Andrew, Sexton, Patrick M. , Xu, Xiequn , Abagyan, Ruben A , Miller, Laurence J.

Mayo Clinic

The FASEB Journal | September 11, 2012 | Volume: 26 | Issue: 12 | Pages: 5092-5105

10.1096/fj.12-212399 | PMID 22964305 Get It

While it is evident that the carboxyl‐terminal region of natural peptide ligands bind to the amino‐terminal domain of class B GPCRs, how their biologically critical amino‐terminal regions dock to the receptor is unclear. We utilize cysteine trapping to systematically explore spatial approximations among residues in the first five positions of secretin and in every position within the receptor extracellular loops (ECLs). Only Cys 2 and Cys 5 secretin analogues exhibited full activity and retained moderate binding affinity (IC 50 : 92±4 and 83±1 nM, respectively). When these peptides probed 61 human secretin receptor cysteine‐replacement mutants, a broad network of receptor residues could form disulfide bonds consistent with a dynamic ligand‐receptor interface. Two distinct patterns of disulfide bond formation were observed: Cys 2 predominantly labeled residues in the amino terminus of ECL2 and ECL3 (relative labeling intensity: Ser 340 , 94±7%; Pro 341 , 84±9%; Phe 258 , 73±5%; Trp 274 62±8%), and Cys 5 labeled those in the carboxyl terminus of ECL2 and ECL3 (Gln 348 , 100%; Ile 347 , 73±12%; Glu 342 , 59±10%; Phe 351 , 58±11%). These constraints were utilized in molecular modeling, providing improved understanding of the structure of the transmembrane bundle and interconnecting loops, the orientation between receptor domains, and the molecular basis of ligand docking. Key spatial approximations between peptide and receptor predicted by this model (H 1 ‐W 274 , D 3 ‐N 268 , G 4 ‐F 258 ) were supported by mutagenesis and residue‐residue complementation studies.—Dong, M., Xu, X., Ball, A. M., Makhoul, J. A., Lam, P. C.‐H., Pinon, D. I., Orry, A., Sexton, P. M., Abagyan, R., Miller, L. J. Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping. FASEB J. 26, 5092–5105 (2012). www.fasebj.org
Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function
Fuchsberger, Christian , Teumer, Alexander , Böger, Carsten A., Endlich, Karlhans , Olden, Matthias , Chen, Ming‐Huei , Li, Man , Gao, Xiaoyi , Gorski, Mathias , Hundertmark, Claudia, Foster, Meredith C., O’Seaghdha, Conall M. , Glazer, Nicole L. , Isaacs, Aaron , Liu, Ching‐Ti , Smith, Albert V. , O’Connell, Jeffrey R. , Struchalin, Maksim , Johnson, Andrew D. , Gierman, Hinco J. , Feitosa, Mary F. , Hwang, Shih-Jen, Atkinson, Elizabeth J. , Lohman, Kurt, Cornelis, Marilyn C., Johansson, Åsa , Tönjes, Anke , Dehghan, Abbas , Lambert, Jean‐Charles , Holliday, Elizabeth G., Sorice, Rossella , Kutalik, Zoltán , Lehtimäki, Terho , Esko, Tõnu , Deshmukh, Harshal , Ulivi, Sheila , Chu, Audrey Y., Murgia, Federico , Trompet, Stella , Imboden, Medea , Coassin, Stefan , Pistis, Giorgio , WTCCC2, Harris, Tamara B., Aspelund, Thor , Eiríksdóttir, Guðný , Mitchell, Braxton D. , Boerwinkle, Eric , Schmidt, Helena , Cavalieri, Margherita, Rao, Madhumathi , Hu, Frank B., Demirkan, Ayşe , Oostra, Ben A., Ding, Jingzhong , Andrews, Jeanette S., Giulianini, Franco, Köenig, Wolfgang , Illig, Thomas, Meisinger, Christa , Gieger, Christian , Zgaga, Lina , Zemunik, Tatijana , Boban, Mladen , Wheeler, Heather E. , Igl, Wilmar , Zaboli, Ghazal, Wright, Alan F., Campbell, Harry, Ellinghaus, David , Nöthlings, Ute , Jacobs, Gunnar, Biffar, Reiner , Ernst, Florian , Kroemer, Heyo K., Stracke, Sylvia , Völker, Uwe , Völzke, Henry , Kovács, Péter , Stümvoll, Michael , Mägi, Reedik , Hofman, Albert , Uitterlinden, André G. , Rivadeneira, Fernando , Aulchenko, Yurii S. , Polašek, Ozren , Hastie, Nick, Vitart, Véronique , Helmer, Catherine , Wang, Jie Jin , Stengel, Bénédicte , Ruggiero, Daniela , Kähönen, Mika , Viikari, Jorma , Nikopensius, Tiit , Province, Michael A. , Ketkar, Shamika , Colhoun, Helen M. , Doney, Alex S. F. , Robino, Antonietta , Krämer, Bernhard K. , Portas, Laura , Ford, Ian, Adam, Martin , Thun, Gian Andri , Paulweber, Bernhard , Haun, Margot, Sala, Cinzia , Mitchell, Paul, Ciullo, Marina , Kim, Stuart K. , Vollenweider, Péter , Raitakari, Olli T., Palmer, Colin, Gasparini, Paolo , Pirastu, Mario, Jukema, J. Wouter , Kronenberg, Florian , Toniolo, Daniela , Guðnason, Vilmundur , Shuldiner, Alan R. , Schmidt, Reinhold, Ferrucci, Luigi , Duijn, Cornelia M. van , Borecki, Ingrid B. , Kardia, Sharon L. R., Rudan, Igor , Pramstaller, Peter P. , Rettig, Rainer, Prokopenko, Inga , Witteman, Jacqueline C.M., Hayward, Caroline , Ridker, Paul M., Parsa, Afshin, Bochud, Murielle , Heid, Iris M. , Kao, W.H. Linda , Fox, Caroline S., Köttgen, Anna , Palmer, Colin N.A. , Chasman, Daniel I. , Pattaro, Cristian , Tin, Adrienne , Taliun, Daniel , Yang, Qiong , Tanaka, Toshiko , Guo, Li , Holliday, Elizabeth G., WTCCC2, Launer, Lenore J. , Andrade, Mariza de , Turner, Stephen T. , Freedman, Barry I. , Minelli, Cosetta , Wild, Sarah H. , Ellinghaus, David , Homuth, Georg , Nauck, Matthias A. , Bergmann, Sven M. , Buckley, Brendan Martin , Metspalu, Andres , Palmer, Colin, Probst-Hensch, Nicole M , Coresh, Josef , Siscovick, David S. , Curhan, Gary C. , Gyllensten, Ulf B , Wilson, James Fox , Franke, André , Palmer, Colin N A , Colhoun, Helen M , Völker, Uwe , Teumer, Alexander , van Duijn, Cornelia M , Smith, Albert V , Mitchell, Braxton D , Shuldiner, Alan R , Ferrucci, Luigi , Koenig, Wolfgang , Kovacs, Peter , Stracke, Sylvia , Liu, Ching-Ti , Wheeler, Heather E , Province, Mike

Mayo Clinic

Human Molecular Genetics | September 8, 2012 | Volume: 21 | Issue: 24 | Pages: 5329-5343

10.1093/hmg/dds369 | PMID 22962313 Get It

Human Lupus Serum Induces Neutrophil-Mediated Organ Damage in Mice That Is Enabled by Mac-1 Deficiency
Rosetti, Florencia , Tsuboi, Naotake , Nishi, Hiroshi , Ernandez, Thomas , Sethi, Sanjeev , Croce, Kevin , Stavrakis, George, Alcocer‐Varela, Jorge, Gómez‐Martín, Diana , Rooijen, Nico van , Lichtman, Andrew H., Mayadas, Tanya N. , Chen, Kan , Kyttaris, Vasileios C. , Tsokos, George C.

Mayo Clinic

The Journal of Immunology | August 30, 2012 | Volume: 189 | Issue: 7 | Pages: 3714-3723

10.4049/jimmunol.1201594 | PMID 22933624 Get It

Abstract Systemic lupus erythematosus (SLE) is a chronic, multiorgan inflammatory autoimmune disorder associated with high levels of circulating autoantibodies and immune complexes. We report that passive transfer of human SLE sera into mice expressing the uniquely human FcγRIIA and FcγRIIIB on neutrophils induces lupus nephritis and in some cases arthritis only when the mice additionally lack the CD18 integrin, Mac-1. The prevailing view is that Mac-1 on macrophages is responsible for immune complex clearance. However, disease permitted by the absence of Mac-1 is not related to enhanced renal immune complex deposition or in situ C1q/C3 complement activation and proceeds even in the absence of macrophages. Instead, disease is associated with increased FcγRIIA-induced neutrophil accumulation that is enabled by Mac-1 deficiency. Intravital microscopy in the cremasteric vasculature reveals that Mac-1 mitigates FcγRIIA-dependent neutrophil recruitment in response to deposited immune complexes. Our results provide direct evidence that human SLE immune complexes are pathogenic, demonstrate that neutrophils are primary mediators of end organ damage in a novel humanized lupus mouse model, and identify Mac-1 regulation of FcγRIIA-mediated neutrophil recruitment as a key step in development of target organ damage.
Frequent expression of fibroblast growth factor-23 (FGF23) mRNA in aneurysmal bone cysts and chondromyxoid fibromas
Graham, Rondell P. , Krishnamurthy, Smita, Oliveira, André M. , Inwards, Carrie Y., Folpe, Andrew L. , Graham, Rondell P

Mayo Clinic

Journal of Clinical Pathology | August 29, 2012 | Volume: 65 | Issue: 10 | Pages: 907-909

10.1136/jclinpath-2012-200852 | PMID 22933546 Get It

Osteomalacia has multiple aetiologies including the least common, tumour-induced osteomalacia (TIO). Recently, most cases of TIO have been confirmed to be due to phosphaturic mesenchymal tumour of mixed connective tissue type (PMTMCT). Most cases of TIO are the result of production of the fibroblast growth factor-23 (FGF-23) by the tumour. The authors recently showed reverse transcriptase PCR (RT-PCR) for FGF-23 to be valuable in the diagnosis of PMTMCT. However, the authors also noted FGF-23 expression in some cases of aneurysmal bone cyst (ABC) and chondromyxoid fibroma (CMF). For the present study, the authors studied FGF-23 expression by RT-PCR in 19 cases of ABC and eight cases of CMF, all with typical clinical and radiographic features and without evidence of TIO. Seven of 16 (44%) ABC and two of seven (29%) CMF were positive for FGF-23. These results confirm that ABC and CMF not uncommonly express FGF-23. These results strongly suggest caution and careful integration with all other clinical and radiographic data in the use of FGF-23 RT-PCR for the diagnosis of PMTMCT.
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group
Husain, Aliya N. , Colby, Thomas V. , Ordóǹez, Nelson G., Krausz, Thomas, Attanoos, Richard , Beasley, Mary Beth , Borczuk, Alain , Butnor, Kelly J. , Cagle, Philip T., Chirieac, Lucian R. , Đačić, Sanja , Fraire, Armando E., Galateau-Sallé, Françoise , Gibbs, A R, Gown, Allen M. , Hammar, Samuel P. , Litzky, Leslie A., Marchevsky, Alberto M. , Roggli, Victor L., Wick, Mark R. , Churg, Andrew , Nicholson, Andrew G. , Travis, William D.

Mayo Clinic

Archives of Pathology and Laboratory Medicine | August 28, 2012 | Volume: 137 | Issue: 5 | Pages: 647-667

10.5858/arpa.2012-0214-oa | PMID 22929121 Get It

Context .—Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. Objective .—To provide updated practical guidelines for the pathologic diagnosis of MM. Data Sources .—Pathologists involved in the International Mesothelioma Interest Group and others with an interest in the field contributed to this update. Reference material includes peer-reviewed publications and textbooks. Conclusions .—There was consensus opinion regarding (1) distinction of benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiation of epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. It is recommended that immunohistochemical markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.
Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
Lee, Eudocia Q. , Kuhn, John G. , Lamborn, Kathleen R., Chang, Susan M. , Drappatz, Jan , Yung, W. K. Alfred, Robins, H. Ian, Lieberman, Frank S. , Lassman, Andrew B. , McGovern, Renee M., Xu, Jihong , Desideri, Serena , Ye, Xiabu, Ames, Matthew M. , Espinoza‐Delgado, Igor, Prados, Michael D. , Wen, Patrick Y. , Puduvalli, Vinay K. , Reid, Joel M. , Cloughesy, Timothy F. , Chang, Susan Marina , Gilbert, Mark R. , Wen, Patrick Yung

Mayo Clinic

Clinical Cancer Research | August 24, 2012 | Volume: 18 | Issue: 21 | Pages: 6032-6039

10.1158/1078-0432.ccr-12-1841 | PMID 22923449 Get It

Abstract Purpose: A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG). Experimental Design: This phase I, dose-finding, investigational study was conducted in two parts. Part 1 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m2/day for 5 days every 28 days. Part 2 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m2/day for 5 days of the first cycle and 200 mg/m2/day for 5 days of the subsequent 28-day cycles. Results: In part 1, the MTD of vorinostat administered on days 1 to 7 and 15 to 21 of every 28-day cycle, in combination with TMZ, was 500 mg daily. Dose-limiting toxicities (DLT) included grade 3 anorexia, grade 3 ALT, and grade 5 hemorrhage in the setting of grade 4 thrombocytopenia. In part 2, the MTD of vorinostat on days 1 to 7 and 15 to 21 of every 28-day cycle, combined with TMZ, was 400 mg daily. No DLTs were encountered, but vorinostat dosing could not be escalated further due to thrombocytopenia. The most common serious adverse events were fatigue, lymphopenia, thrombocytopenia, and thromboembolic events. There were no apparent pharmacokinetic interactions between vorinostat and TMZ. Vorinostat treatment resulted in hyperacetylation of histones H3 and H4 in peripheral mononuclear cells. Conclusion: Vorinostat in combination with temozolomide is well tolerated in patients with HGG. A phase I/II trial of vorinostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway. Clin Cancer Res; 18(21); 6032–9. ©2012 AACR.
Effect of a neurohospitalist service on outcomes at an academic medical center
Douglas, Vanja C. , Berg, Geraldine, Freeman, William D. , Josephson, S. Andrew , Scott, Brian J. , Freeman, William D

Mayo Clinic

Neurology | August 23, 2012 | Volume: 79 | Issue: 10 | Pages: 988-994

10.1212/wnl.0b013e31826846cb | PMID 22914833 Get It

Faculty Opinions recommendation of Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.
Trushin, Sergey , Badley, Andrew D.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1165504.723055 Get It